Shares of 4d Pharma PLC (LON:DDDD) rose 1.4% during trading on Wednesday . The stock traded as high as GBX 95.35 ($1.25) and last traded at GBX 95.35 ($1.25), approximately 10,474 shares were traded during mid-day trading. A decline of 37% from the average daily volume of 16,686 shares. The stock had previously closed at GBX 94 ($1.23).
The company has a quick ratio of 6.11, a current ratio of 6.41 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $62.22 million and a P/E ratio of -2.62. The business has a 50-day moving average of GBX 94.63.
In other news, insider David Robert Norwood acquired 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The stock was acquired at an average cost of GBX 100 ($1.31) per share, with a total value of £15,000 ($19,600.16).
4D pharma plc engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease, as well as Rosburix for Paediatric Ulcerative Colitis. It also develops immuno-oncology products, including MRx0518 for solid tumors; respiratory products, such as MRx0004 for asthma and MRx0001 for allergic asthma; autoimmune products comprising MRx0002 for multiple sclerosis and MRx0006 for rheumatoid arthritis; and CNS products for autism.
Receive News & Ratings for 4d Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4d Pharma and related companies with MarketBeat.com's FREE daily email newsletter.